专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO2012028334A3 MARKER FOR SUNITINIB RESISTANCE FORMATION 审中-公开
公开(公告)号：WO2012028334A3
公开(公告)日：2012-03-08
申请号：PCT/EP2011/004566
申请日：2011-09-05
申请人： MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER FÖRDERUNG DER WISSENSCHAFTEN E.V. , BENDER, Claus , ULLRICH, Axel
发明人： BENDER, Claus , ULLRICH, Axel
IPC分类号： C12Q1/68
摘要： The present invention relates to marker for sunitinib resistance formation and modulators thereof for the prevention and reduction of sunitinib resistance of hyperproliferative cells, in particular cancer cells. Further, the present invention relates to compositions comprising agents suitable for anticancer therapy in combination with the modulators for treating proliferative diseases.

12. 发明申请

WO2008052798A3 FGFR4 PROMOTES CANCER CELL RESISTANCE IN RESPONSE TO CHEMOTHERAPEUTIC DRUGS 审中-公开
公开(公告)号：WO2008052798A3
公开(公告)日：2008-05-08
申请号：PCT/EP2007/009533
申请日：2007-11-02
申请人： MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. , ULLRICH, Axel , BERGER, Hans-Jürgen , ROIDL, Andreas
发明人： ULLRICH, Axel , BERGER, Hans-Jürgen , ROIDL, Andreas
IPC分类号： C12N15/11 , C07K16/28 , C12Q1/68 , A61K31/713 , A61K39/395 , C07K14/71 , A61P35/00
摘要： The present invention relates to Fibroblast-Growth Factor Receptor 4 (FGRF4) inhibitors for co-administration with a therapeutic procedure or/and agent for the prevention, alleviation or/and treatment of a hyperproliferative disorder, e.g. cancer, such as chemotherapy resistant cancer. Further, the present invention relates to a diagnostic procedure wherein expression status and/or polymorphisms of the FGFR4 gene are determined in a patient suffering from a hyperproliferative disorder, e.g. cancer. Based on the results of this determination and the status of the disorder to be treated a therapeutic protocol may be developed. Yet another subject of the present invention is a screening method.

13. 发明申请

WO2002060470A1 PYK2 PHOSPHORYLATION BY HER3 INDUCES TUMOR INVASION 审中-公开
标题翻译： PYK2由其诱导肿瘤侵袭引起的磷酸化
公开(公告)号：WO2002060470A1
公开(公告)日：2002-08-08
申请号：PCT/EP2002/001015
申请日：2002-01-31
申请人： MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. , ULLRICH, Axel , VAN DER HORST, Edward, Htun
发明人： ULLRICH, Axel , VAN DER HORST, Edward, Htun
IPC分类号： A61K38/17
CPC分类号： A61K38/179 , C12Q1/485 , G01N2500/00
摘要： The present invention relates to the use of a HER2 protein or a nucleic acid coding therefor as a target for the modulation of the mitogen-activated protein (MAP) kinase pathway. Further, the use of a PYK2 protein and a nucleic acid coding therefor as a target for the modulation of the MAP kinase pathway is described. By inhibiting HER3 kinase activity, the phosphorylation of PYK2 and thus the stimulation of the MAP kinase pathway is inhibited. The present invention is preferably suitable for applications, particularly diagnostic or medical applications, wherein an inhibition of the MAP kinase pathway is desired. Thus, the invention relates to novel methods for diagnosing, treating or preventing MAP kinase associated disorders such as tumors.
摘要翻译：本发明涉及HER2蛋白或其编码的核酸作为调节丝裂原活化蛋白（MAP）激酶途径的靶标的用途。此外，描述了使用PYK2蛋白和其编码的核酸作为调节MAP激酶途径的靶标。通过抑制HER3激酶活性，抑制PYK2的磷酸化，从而抑制MAP激酶途径的刺激。本发明优选适用于需要抑制MAP激酶途径的应用，特别是诊断或医学应用。因此，本发明涉及用于诊断，治疗或预防MAP激酶相关疾病如肿瘤的新方法。

14. 发明申请

WO1994021800A2 PROTEIN TYROSINE PHOSPHATASE PTP-S31 审中-公开
标题翻译：蛋白酪氨酸磷酸酯酶PTP-S31
公开(公告)号：WO1994021800A2
公开(公告)日：1994-09-29
申请号：PCT/EP1994000909
申请日：1994-03-23
申请人： MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
发明人： MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. , MOLLER, Niels, P., H. , MOLLER, Karin, B. , ULLRICH, Axel
IPC分类号： C12N15/55
CPC分类号： C12N9/16 , A61K38/00
摘要： A protein tyrosine phosphatase designated PTP-S31 and its subfamily are identified, as are nucleic acid molecules coding therefor. Included in this family are PTP-S31 proteins or glycoproteins having one, two, or three identified amino acid changes in previously defined consensus sequences in the catalytic phosphatase domains of known protein tyrosine phosphatases. The PTP-S31 proteins or glycoproteins may be produced by recombinant means. Antibodies to PTP-S31 proteins or glycoproteins and nucleic acid constructs coding therefor, and methods for screening molecules which can bind to PTP-S31 proteins or glycoproteins and inhibit or stimulate their enzymatic activity, are provided.
摘要翻译：鉴定了称为PTP-S31及其亚科的蛋白酪氨酸磷酸酶，以及编码它的核酸分子。该家族包括PTP-S31蛋白或糖蛋白，其在已知蛋白酪氨酸磷酸酶的催化磷酸酶结构域中具有一个，两个或三个鉴定的氨基酸变化。 PTP-S31蛋白或糖蛋白可以通过重组方法产生。提供了针对PTP-S31蛋白或糖蛋白的抗体及其编码的核酸构建体，以及用于筛选可结合PTP-S31蛋白或糖蛋白并抑制或刺激其酶活性的分子的方法。

15. 发明申请

WO1994021781A2 EXTRACELLULAR SIGNAL-REGULATED KINASE, SEQUENCES, AND METHODS OF PRODUCTION AND USE 审中-公开
标题翻译：细胞外信号调控激酶，序列及其生产和使用方法
公开(公告)号：WO1994021781A2
公开(公告)日：1994-09-29
申请号：PCT/IB1994000089
申请日：1994-03-18
申请人： MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
发明人： MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. , LECHNER, Cornelia , MOLLER, Neils, Peter, H. , ULLRICH, Axel
IPC分类号： C12N00/00
CPC分类号： C07K16/40 , A61K38/00 , A61K48/00 , C07K2319/00 , C12N9/12 , C12N2799/021 , Y10S530/809
摘要： The present invention relates, in general, to an extracellular signal regulated kinase, ERK-5. In particular, the present invention relates to nucleic acid molecules coding for ERK-5; ERK-5 polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antisense ERK-5 nucleic acid constructs; antibodies having binding affinity to an ERK-5 polyppetide; hybridomas containing the antibodies; nucleic acid probes for the detection of ERK-5 nucleic acid; a method of detecting ERK-5 nucleic acid or polypeptide in a sample; kits containing nucleic acid probes or antibodies; a method of detecting a compound capable of binding to ERK-5 or a fragment thereof; a method of detecting an agonist or antagonist of ERK-5 activity; a method of agonizing or antagonizing ERK-5 associated activity in a mammal; a method of treating diabetes mellitus, skeletal muscle diseases, Alzheimer's disease, or peripheral neuropathies in a mammal with an agonist or antagonist of ERK-5 activity; and a pharmaceutical composition comprising an ERK-5 agonist or antagonist.
摘要翻译：本发明一般涉及细胞外信号调节激酶ERK-5。特别地，本发明涉及编码ERK-5的核酸分子; ERK-5多肽; 重组核酸分子; 含有重组核酸分子的细胞; 反义ERK-5核酸构建体; 具有与ERK-5多核苷酸结合亲和力的抗体; 含有抗体的杂交瘤; 用于检测ERK-5核酸的核酸探针; 在样品中检测ERK-5核酸或多肽的方法; 含有核酸探针或抗体的试剂盒; 检测能够结合ERK-5或其片段的化合物的方法; 检测ERK-5活性的激动剂或拮抗剂的方法; 在哺乳动物中激动或拮抗ERK-5相关活性的方法; 在具有ERK-5活性的激动剂或拮抗剂的哺乳动物中治疗糖尿病，骨骼肌疾病，阿尔茨海默氏病或周围神经病变的方法; 和包含ERK-5激动剂或拮抗剂的药物组合物。

16. 发明申请

WO1994003611A2 PTP-D SUBFAMILY OF PROTEIN TYROSINE PHOSPHATASES 审中-公开
标题翻译：蛋白酪氨酸磷酸酯的PTP-D亚型
公开(公告)号：WO1994003611A2
公开(公告)日：1994-02-17
申请号：PCT/EP1993002086
申请日：1993-08-05
申请人： MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER ...
发明人： MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER ... , ULLRICH, Axel , MOLLER, Nils, Peter, Hundahl , BACH-MOLLER, Karin
IPC分类号： C12N15/55
CPC分类号： C12N9/16 , A61K38/00 , C07K2319/00 , C12Q1/42 , G01N33/573
摘要： A novel subfamily (PTP-D) of protein tyrosine phosphatases is identified. Included in this family are PTP-D proteins or glycoproteins having one, two, or three identified amino acid changes in previously defined consensus sequences in the catalytic phosphatase domains of known protein tyrosine phosphatases. The PTP-D proteins or glycoproteins may be produced by recombinant means. Antibodies to PTP-D proteins or glycoproteins and nucleic acid constructs coding therefor, and methods for screening molecules which can bind to PTP-D proteins or glycoproteins and inhibit or stimulate their enzymatic activity, are provided.
摘要翻译：鉴定出蛋白酪氨酸磷酸酶的新亚科（PTP-D）。该家族包括在已知蛋白酪氨酸磷酸酶的催化磷酸酶结构域中的先前确定的共有序列中具有一个，两个或三个鉴定的氨基酸变化的PTP-D蛋白或糖蛋白。 PTP-D蛋白或糖蛋白可以通过重组方法产生。提供了对PTP-D蛋白或糖蛋白及其编码的核酸构建体的抗体以及用于筛选可结合PTP-D蛋白或糖蛋白并抑制或刺激其酶活性的分子的方法。

17. 发明申请

WO1993016180A1 SEQUENCES FOR A 90K TUMOR-ASSOCIATED ANTIGEN, IMMUNOREGULIN-95 (IR-95) 审中-公开
标题翻译： 90K肿瘤相关抗原，免疫调节素-95（IR-95）的序列
公开(公告)号：WO1993016180A1
公开(公告)日：1993-08-19
申请号：PCT/EP1993000382
申请日：1993-02-17
申请人： MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER ... , UNIVERSITA' DEGLI STUDI ''G.D'ANNUNZIO''-CHIETI
发明人： MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER ... , UNIVERSITA' DEGLI STUDI ''G.D'ANNUNZIO''-CHIETI , ULLRICH, Axel , SURES, Irmingard , AZAM, Mohammad , IACOBELLI, Stefano , NATOLI, Clara
IPC分类号： C12N15/12
摘要： This invention provides substantially purified tumor-associated 90K antigen, or fragment(s) thereof, especially from: the culture fluid of the human breast cancer cell line, CG-5; the serum of a breast cancer patient; or the ascitic fluid from an ovarian cancer patient. The native antigen, which has a molecular weight of about 95,000 daltons, is present as a high molecular weight complex. The purification and characterization of the antigen is provided as well as uses thereof. The nucleotide sequences which encode the 90K antigen, or fragment(s) thereof, vehicles containing the genetic sequence, hosts transformed therewith, and production of the antigen, or fragments thereof, by the transformed host are also provided.

18. 发明申请

WO2011070150A1 NOVEL TARGETS FOR THE TREATMENT OF PROLIFERATIVE DISEASES 审中-公开
标题翻译：治疗增殖性疾病的新目标
公开(公告)号：WO2011070150A1
公开(公告)日：2011-06-16
申请号：PCT/EP2010/069369
申请日：2010-12-10
申请人： MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. , ULLRICH, Axel , BAIRLEIN, Michaela
发明人： ULLRICH, Axel , BAIRLEIN, Michaela
IPC分类号： C07K14/82 , C12N15/113 , G01N33/50 , A61P35/04 , C07D417/14
CPC分类号： C12N15/1137 , C12N15/1135 , C12N2310/11 , C12N2310/12 , C12N2310/14 , C12Y207/04006 , C12Y207/10001 , C12Y207/11001 , G01N33/57484 , G01N2500/04
摘要： The present invention relates to novel target structures and modulators thereof for the prevention, diagnosis, prognosis and treatment of hyperproliferative and/or metastatic disorders, in particular cancer diseases. The novel targets are useful for the identification, characterization and development of novel effective anti-tumor drugs. Further, the present invention relates to compositions comprising agents suitable for anticancer therapy and to novel approaches for combating hyperproliferative and/or metastatic diseases.
摘要翻译：本发明涉及用于预防，诊断，预后和治疗过度增生和/或转移性疾病，特别是癌症疾病的新型靶结构及其调节剂。该新颖的靶标对于新型有效的抗肿瘤药物的鉴定，表征和开发是有用的。此外，本发明涉及包含适合于抗癌治疗的药物和用于防治过度增殖和/或转移性疾病的新方法的组合物。

19. 发明申请

WO2011070148A1 DIFFERENTIAL DIAGNOSIS AND THERAPY FOR KINASE INHIBITORS 审中-公开
标题翻译：激酶抑制剂的差异诊断和治疗
公开(公告)号：WO2011070148A1
公开(公告)日：2011-06-16
申请号：PCT/EP2010/069367
申请日：2010-12-10
申请人： MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. , ULLRICH, Axel , BAIRLEIN, Michaela
发明人： ULLRICH, Axel , BAIRLEIN, Michaela
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： The present invention relates to novel methods and compositions for prognosing the effectiveness of kinase inhibitors such as sunitinib in the therapy of hyperproliferative and particularly metastatic diseases. Thus, the invention allows the development of individually adapted strategies for treating conditions associated with and/or caused by the occurrence of a given type of hyperproliferating and/or metastatic cells.
摘要翻译：本发明涉及用于预测激素抑制剂如舒尼替尼在过度增殖和特别是转移性疾病的治疗中的有效性的新方法和组合物。因此，本发明允许开发用于治疗与特定类型的过度增殖和/或转移细胞的发生相关和/或由其引起的单独适应的策略。

20. 发明申请

WO2005004893A2 INHIBITION OF STRESS-INDUCED LIGAND-DEPENDENT EGFR ACTIVATION 审中-公开
标题翻译：抑制应激诱导的配体依赖性EGFR激活
公开(公告)号：WO2005004893A2
公开(公告)日：2005-01-20
申请号：PCT/EP2004/007329
申请日：2004-07-05
申请人： MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. , ULLRICH, Axel , FISCHER, Oliver
发明人： ULLRICH, Axel , FISCHER, Oliver
IPC分类号： A61K38/00
CPC分类号： C12N15/1137 , A61K39/3955 , A61K45/06 , C12N2310/14 , A61K2300/00
摘要： The present invention relates to the inhibition of stress-induced receptor tyrosine kinase activity by inhibiting a ligand of said receptor tyrosine kinase, particularly an extracellular ligand.
摘要翻译：本发明涉及通过抑制所述受体酪氨酸激酶的配体，特别是细胞外配体来抑制应激诱导的受体酪氨酸激酶活性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式